Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy?

Suzan Tabur1, Hakan Korkmaz1*, Mesut Ozkaya1, Sefika Nur Aksoy2 and Ersin Akarsu1

Abstract

Background: In the present study, we aimed to investigate serum calprotectin levels in patients with diabetic peripheral neuropathy, and possible role of this molecule in the disease pathogenesis.

Method: Twenty nine patients with diabetic peripheral neuropathy, 30 type 2 diabetic patients without neuropathy, and 40 healthy controls were enrolled in the study. Fasting plasma glucose (FPG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), total cholesterol, triglyceride, HbA1c, calprotectin and hsCRP levels were measured in diabetic and healthy control groups.

Results: Serum calprotectin and hsCRP levels were significantly higher in patients with and without neuropathy than healthy controls (p < 0.001, p = 0.017, p < 0.001 and p = 0.001, respectively). Serum calprotectin and hsCRP levels were higher in diabetics with neuropathy than the ones without (p = 0.021 and p < 0.001, respectively). The positive correlation was detected between calprotectin levels and hsCRP and HbA1c in Spearman correlation analysis (r = 0.510, p < 0.001; r = 0.437, p < 0.001 respectively). The results of multiple logistic regression analysis demonstrated the important association between neuropathy development and hsCRP and serum calprotectin levels in diabetic individuals.

Conclusion: Seum calprotectin levels were increased in diabetic peripheral neuropathy. It may have a role in the pathogenesis of the disease.

Keywords: Calprotectin, Inflammation, Diabetic peripheral neuropathy

Introduction

Diabetes is encountered as one of the most challenging healthcare problems in the 21st century, and its prevalence is higher in developing countries. While for year 2030, 170% increase is expected for developing countries, 42% increase is expected for developed countries [1]. The most commonly encountered microvascular complication of type 2 diabetes is diabetic neuropathy with the prevalence of 50-60%. Neuropathy may cause decreased nerve functions and nerve blood perfusion with persistent nerve damage. Diabetic peripheral polyneuropathy increases development of foot ulceration risk, and also it increases developmental risk of necrosis, which may cause lower extremity amputations. Diabetic peripheral polyneuropathy has significant contributions in morbidity and mortality in diabetic patients [2,3].

Although it is predicted that hyperglycemia is an important pathophysiological factor in development of diabetic neuropathy, the related mechanisms have not been totally clarified. Opinions suggesting that inflammatory processes may play a role in pathogenesis of diabetic polyneuropathy are increasing. In previous studies, it has was shown that peripheral neuropathy was associated with increased levels of proinflammatory immune mediators in patients with type 2 diabetes [4,5].

Calprotectin (myeloid related protein 8/14) is a stable heterodimer belonging to S100 protein family composed of two calcium binding cytoplasmic calgranulins which are expressed in activated human granulocyte and macrophages in inflammatory conditions. Among its functions...
are activations of NADPH oxidase, toll like receptors 4 (TLR4), and advanced glycation end products (AGEs) receptors, which are important signalling pathways in pathogenesis of micro- and macrovascular complications of diabetes [6-8].

In the present study, we aimed to investigate serum calprotectin levels in patients with peripheral neuropathy, and possible role of this molecule in the disease pathogenesis.

**Material and method**

The present prospective study was conducted in the department of Endocrinology at Medical School of Gaziantep University. Twenty nine patients with diabetic peripheral neuropathy, 30 type 2 diabetic patients without neuropathy, and 40 healthy controls were enrolled in the study.

Patients with diabetic peripheral neuropathy had symptomatic symmetrical distal neuropathy (i.e., hypoactive deep tendon reflexes, reduced tactile, pinprick, and/or position sensation) with at least moderate severity of one or more of the typical symptoms (pain, burning, paresthesia, numbness or cramps) in the lower extremities.

The diagnosis of diabetic peripheral neuropathy was made according to clinical symptoms, neurologic examination and electrophysiologic investigation. Nerve conduction studies were performed with a standard electromyography equipment.

Subjects had infectious diseases, inflammatory diseases, liver failure, malignancies, neurodegenerative diseases, renal failure, cerebrovascular diseases, medical history of serious trauma to the limbs, use of neurotoxic medication, B12 vitamin deficiency, excessive alcohol consumption and smokers were excluded from the study both in study and control groups.

Age, weight, height, body mass index (BMI: body weight (kg)/height (cm)²), and systolic (SBP) and diastolic blood pressures (DBP) of all subjects were recorded. Blood samples were collected in the morning after an 8-hour fasting period. Serum samples were stored at −80°C until calprotectin levels were measured. Fasting plasma glucose (FPG), high-density lipoprotein- cholesterol (HDL-C), low-density lipoprotein- cholesterol (LDL-C), total cholesterol, triglyceride (TG), HbA1c, high sensitive C-reactive protein (hsCRP) levels were measured in diabetic and healthy control groups.

The concentration of serum calprotectin was determined using an enzyme-linked immunosorbent assay detection kit (Hycult biotec, HK325, Human Calprotectin ELISA kit, NLD).

FPG, HDL-C, LDL-C, total cholesterol (Total-C), TG levels were measured by electrochemiluminescence method using Cobas Integra 800 model auto-analyzer (Roche Diagnostics, Germany). HbA1c levels were measured by HPLC.

**Table 1 Clinical and metabolic parameters of the diabetic patients with or without neuropathy and healthy control groups**

|                        | DNP(+) | DNP(−) | HC    | P DNP(+)-DNP(−) | p DNP(+)-HC | P DNP(−)-HC |
|------------------------|--------|--------|-------|-----------------|-------------|-------------|
| Age (years)*           | 52.59 (±13.56) | 49.83 (±12.65) | 47.15 (±7.21) | 0.424           | 0.262       | 0.125       |
| Gender (M/F)           | 11/18  | 15/15  | 13/14 | 0.435           | 0.590       | 0.550       |
| BMI (kg/m²)            | 34.80 (±11.90) | 40.61 (±3.70) | 26.64 (±2.26) | <0.001          | 0.001       | 0.001       |
| SBP (mmHg)             | 130.00 (±20.00) | 135.00 (±10.00) | 120 (±15.00) | 0.042           | 0.054       | <0.001      |
| DBP (mmHg)             | 80 (±20.47) | 80 (±13.00) | 75.00 (±10.00) | 0.174           | 0.026       | <0.001      |
| FPG (mg/dl)            | 205 (±97.00) | 117 (±32.00) | 87 (±13.00) | <0.001          | 0.001       | 0.001       |
| HbA1c (%)              | 10.10 (±3.50) | 7.15 (±1.10) | 5.10 (±0.50) | <0.001          | 0.001       | 0.001       |
| Total-C (mg/dl)        | 180.50 (±71.00) | 222.00 (±38.00) | 109 (±28.00) | 0.001           | 0.528       | <0.001      |
| HDL-C (mg/dl)          | 38.50 (±17.00) | 48.50 (±8.00) | 50.00 (±9.00) | 0.003           | 0.002       | 0.183       |
| LDL-C (mg/dl)*         | 115.61 (±40.09) | 141.77 (±27.91) | 105.26 (±25.30) | 0.004          | 0.441       | <0.001      |
| TG (mg/dl)             | 214.00 (±95.00) | 173.50 (±67.00) | 136.00 (±39.00) | 0.041          | <0.001      | 0.001       |
| Creatinine (mg/dl)     | 0.85 (±0.29) | 0.86 (±0.16) | 0.89 (±0.11) | 0.167           | 0.102       | 0.163       |
| Duration of DM (years) | 6 (±2.00) | 3 (±1.00) | 3 (±1.00) | 0.001           |           |            |
| Calprotectin (ng/dl)*   | 8.30 (±1.48) | 7.41 (±1.26) | 6.18 (±1.58) | 0.021           | <0.001      | 0.017       |
| hsCRP (mg/dl)          | 52.59 (±13.56) | 2.40 (±2.34) | 1.12 (±0.41) | <0.001          | <0.001      | 0.001       |
| Medical Treatment       | 11/18  | 14 (46.7%) | 5 (16.7%) | 0.141           |           |            |
| OAD (n, %)             | 34.80 (±11.90) | 14 (46.7%) |        |                |           |            |
| Insulin (n, %)         | 130.00 (±20.00) | 5 (16.7%) |        |                |           |            |
| OAD + Insulin (n, %)   | 80 (±20.47) | 11 (36.7%) |        |                |           |            |

Body Mass Index, BMI; Fasting Blood Glucose; High density lipoprotein cholesterol, HDL-C; High sensitive C reactive protein, hsCRP; Low density lipoprotein cholesterol, LDL-C; Triglyceride, TG.
high performance liquid chromatography) method using Trinity Biotech-Premier Hb9210 auto-analyzer. Standard biochemistry tubes with gel were also used for the measurement of hsCRP levels with immunonephelometry assay on Dade Behring Nephelometer II device.

The study was initiated upon obtaining approval from Ethics Committee of Medical School at Gaziantep University (23.06.2014/246). Informed consent was obtained from all subjects prior to the study.

Statistical analysis
Shapiro-Wilk test was used to test continuous variables for normality. Measurements of normally distributed variables (age, LDL-C) are presented as mean ± standard deviation. Those with non-normal distributions are presented as median and interquartile range (IQR). Student's t-test was used in comparison of 2 independent groups of normally distributed variables; one-way analysis of variance (ANOVA) test was used when comparing more than 2 groups; and LSD test was used for paired comparisons to identify which group the difference was caused by. For non-normally distributed variables, Mann–Whitney U test was used to compare 2 independent groups and Kruskall Wallis test was used to compare more than 2 independent groups. DUNN test was used for post-hoc comparisons. Spearman correlation analysis was done to identify associations between the parameters in diabetic patients. Multiple linear regression analysis was conducted to identify the variables impacting the calprotectin level. Multiple logistic regression analysis was done to evaluate the relationship between neuropathy and calprotectin, hsCRP and BMI in diabetic patients. SPSS for Windows version 15 software was used for statistical analyses. The level of significance was set at $p \leq 0.05$.

Results
The mean age of all 3 groups and their gender distribution were similar ($p = 0.077$ and $p = 0.609$, respectively). BMI, FPG, and HbA1c levels of diabetic patients with and without neuropathy were significantly higher than the controls ($p = 0.001$, for each). While FPG and HbA1c levels in patients with neuropathy were significantly higher than patients without neuropathy; BMI in the former group was significantly lower than in the latter group ($p < 0.001$, for each; Table 1).

Serum calprotectin and hsCRP levels were significantly higher in patients with and without neuropathy than healthy controls ($p < 0.001$, $p = 0.017$, $p < 0.001$ and

![Figure 1](image_url)
Serum calprotectin and hsCRP levels were higher in diabetics with neuropathy than the ones without (p = 0.021 and p < 0.001, respectively). Total-C, HDL-C and LDL-C levels were determined lower (p = 0.041, p = 0.001, p = 0.003, p = 0.004, respectively). Total-C, LDL-C and TG levels were determined significantly higher in diabetic patients without neuropathy than healthy controls (p < 0.001, p < 0.001 and p = 0.001, respectively). TG levels in diabetic patients with neuropathy were higher than the control group, whereas HDL levels were lower (p < 0.001, p = 0.002). There was no significant difference in LDL and total-C levels between patients with neuropathy and healthy controls (p = 0.441, p = 0.528).

The correlations between calprotectin and other clinical and laboratory parameters were shown in Table 2. The positive correlation was detected between calprotectin levels and hsCRP and HbA1c in Spearman correlation analysis (r = 0.510, p < 0.001; r = 0.437, p < 0.001 respectively; Figures 2 and 3).

Multiple logistic regression analysis results demonstrated the important association between neuropathy development and hsCRP and serum calprotectin levels in diabetic individuals (Table 3).

**Discussion**

The present study is the first study describing the correlation between calprotectin and diabetic peripheral neuropathy in type 2 diabetic patients.

| Table 2 Correlations between calprotectin, and other clinical and metabolic parameters in diabetic patients |
|-----------------------------------|---|---|---|---|---|---|---|---|
| | BMI | SBP | DBP | HDL-C | LDL-C | TG | FBP | HbA1C |
| Calprotectin | | | | | | | | |
| R | 0.147 | 0.061 | 0.135 | −0.166 | −0.028 | 0.192 | 0.221 | 0.437 | 0.510 |
| P | 0.177 | 0.577 | 0.215 | 0.129 | 0.796 | 0.077 | 0.041 | <0.001 | <0.001 |
| BMI | | | | | | | | |
| R | 0.237 | 0.146 | 0.097 | 0.126 | −0.501 | 0.117 | 0.180 | 0.175 |
| P | 0.028 | 0.180 | 0.377 | 0.246 | 0.641 | 0.285 | 0.096 | 0.188 |
| SBP | | | | | | | | |
| R | 0.611 | 0.228 | 0.239 | −0.051 | 0.003 | 0.112 | −0.030 |
| P | <0.001 | 0.036 | 0.027 | 0.641 | 0.982 | 0.303 | 0.823 |
| DBP | | | | | | | | |
| R | 0.259 | 0.155 | −0.158 | 0.070 | 0.150 | 0.19 | |
| P | 0.017 | 0.153 | 0.146 | 0.523 | 0.169 | 0.887 |
| HDL-C | | | | | | | | |
| R | 0.460 | 0.077 | 0.391 | 0.271 | −0.224 |
| P | <0.001 | 0.484 | <0.001 | 0.012 | 0.094 |
| LDL-C | | | | | | | | |
| R | 0.171 | 0.224 | 0.070 | −0.328 |
| P | 0.116 | 0.038 | 0.522 | 0.012 |
| TG | | | | | | | | |
| R | 0.587 | 0.324 | −0.047 |
| P | <0.001 | 0.002 | 0.726 |
| FBG | | | | | | | | |
| R | 0.729 | 0.207 |
| P | <0.001 | 0.120 |
| HbA1C | | | | | | | | |
| R | 0.203 |
| P | 0.127 |

Data were expressed as median (±IQR) and *mean (±SD). *Mann–Whitney U and *Student’s t-test was used in comparison of 2 independent group. DM with neuropath group, DNP (+); DM without neuropath group, DNP (−); Healthy control group, HC; Body Mass Index, BMI; Systolic blood pressure, SBP; Diastolic blood pressure; Fasting blood glucose; High density lipoprotein cholesterol, HDL-C; Triglyceride, TG; Low density lipoprotein cholesterol, LDL-C; High sensitive C reactive protein, hsCRP; Oral antidiabetic drug, OAD.
Calprotectin, belonging to S100 protein family, a heterodimer of two intracellular, calcium-binding proteins (S100A8 and S100A9 also referred to as MRP8 and MRP14), is critically involved in proinflammatory signalling. It is proposed that calprotectin complex is a biomarker for inflammation, and is beneficial in monitoring disease activity. High levels of calprotectin levels are reported in chronic inflammatory diseases such as rheumatoid arthritis, allograft rejection, inflammatory bowel disease, cancer, pulmonary disease, obesity, atherosclerosis [6,9,10].

Diabetic peripheral neuropathy is characterized by debilitating pain, which deteriorates the life quality, and sensation loss. It was believed that activation of inflammatory cascade, proinflammatory cytokine upregulation, and neuroimmune communication pathways are important in structural and functional nerve damage, which caused development of diabetic peripheral neuropathy. It was proposed that AGE had an important role during this process [3,11].

The finding that AGEs stimulating signal transduction cascades through multiligand receptor the receptor for advanced glycation end products (RAGE) unveiled novel insights into diabetes and its complications. RAGE is a multi-ligand receptor interacting with certain members of S100/calgranulin family, and implicates the receptor in inflammatory disorders [12-14].

The association of Nuclear factor-kappa B (NF-κB) activation with diabetic neuropathy has been shown in Mouse models. NF-κB is a transcription factor that is involved in the control of large number of cellular processes, such as immun and inflammatory responses. Toll-like receptors can activate NF-κB and cause an increase in expression of several inflammatory mediators. Calprotectin has also been identified as endogenous activator of TLR4 [11,15].

These mechanisms suggest that calprotectin may be an inflammatory marker, which has a role in pathogenesis of diabetic peripheral neuropathy.

So far, relationship between circulating levels of calprotectin and glucose homeostasis has been shown in few studies. Ortega et al. reported plasma levels of calprotectin associated with insulin resistance and low-grade inflammation in type 2 diabetic patients [16]. Schmaderer et al. addressed a correlation between calprotectin and

![Figure 2](image-url)  
Figure 2 Correlation between serum calprotectin levels and HbA1C in diabetic patients.
microalbuminuria; a predictive marker of cardiovascular disease in type 2 diabetic patients [17]. Peng et al. reported that increased serum calprotectin level was associated with atherosclerosis in type 2 diabetic patients [8]. In the present study, we determined higher calprotectin levels in diabetic peripheral neuropathy, which is the most commonly encountered microvascular complication in type 2 diabetics, when compared with diabetics without neuropathy and healthy controls.

In this study, calprotectin correlated significantly with hs-CRP levels supporting the role of calprotectin as an inflammation marker. Similar to our results, positive correlation was reported between calprotectin and hs-CRP in a few previous studies [8,18]. On the other hand, there was also a positive correlation between calprotectin and HbA1c, the marker of long-term elevation of blood sugar. This result suggests that levels of glucose or glycation products may affect regulation of high calprotectin levels in diabetic complications.

In conclusion, high levels of calprotectin detected in type 2 diabetic patients with peripheral neuropathy suggest that this molecule may have a role in pathogenesis of neuroinflammation among these patients. Serum calprotectin levels in the future may be used as potential markers of its presence, severity, and progression of diabetic peripheral neuropathy. Therapeutic strategies for blocking S100A9 and its activity are recently under development in inflammatory diseases [19]. Therefore, the data from our study also support calprotectin as a drug target in diabetic peripheral neuropathy.

**Table 3 Results of logistic regression models predicting neuropathy**

| Risk Factor   | OR (95% CI)       | P value |
|---------------|-------------------|---------|
| Calprotectin  | 1.771 (1.104-2.840) | 0.018*  |
| hsCRP         | 1.043 (1.005-1.082) | 0.027*  |
| BMI           | 0.976 (0.938-1.017) | 0.247   |

*Significant at p < 0.05. Calprotectin, hsCRP; Body Mass Index, BMI.

**Abbreviations**

BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; Total-C: Total cholesterol; HDL-C: High density lipoprotein-cholesterol; TG: Triglyceride; LDL-C: Low density lipoprotein-cholesterol; hsCRP: High sensitive C-reactive protein; AGE: Advanced glycation and products; TLR4: Toll like receptors 4; NF-κB: Nuclear factor- kappa B; RAGE: Receptor for advanced glycation end products.
Competing interests

The authors declare that they have no competing interest that could be perceived as prejudicing the impartiality of the research reported.

Authors’ contributions

ST and HK conceptualized the idea for the study, collected the data, performed a literature review, and wrote the manuscript. ST, HK, and MO participated in the design of the study, participated in the discussion, and was involved in drafting the manuscript. HK and ST were involved in performing the statistical analysis. EA and SNA participated in the discussion. All the authors have read and approved the final manuscript.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author details

1Department of Internal Medicine, Division of Endocrinology, Gaziantep University, Faculty of Medicine, 27100 Sahinbey, Gaziantep, Turkey.
2Department of Clinical Biochemistry, Gaziantep University, Faculty of Medicine, 27100 Sahinbey, Gaziantep, Turkey.

Received: 9 January 2015 Accepted: 2 April 2015

Published online: 24 April 2015

References

1. Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab. 2014;25:15–22.
2. Vinik AI, Nevolet ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42:747–87.
3. Sandireddy R, Yerra VG, Areli A, Komirshetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. Int J Endocrinol. 2014;2014:74987.
4. Singh R, Kishore L, Kaur N. Peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21–35.
5. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study. Diabetes Care. 2013;36:6663–70.
6. Stifz I, Trebichavský I. Calprotectin a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–53.
7. Sekimoto R, Kishida K, Nakatsuji H, Nakagawa T, Funahashi T, Shimomura I. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun. 2012;419:782–9.
8. Peng WH, Jian WX, Li HL, Hou L, Wei YD, Li WM, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011;10:41.
9. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, et al. Calprotectin-a novel marker of obesity. PLoS One. 2009;4, e7419.
10. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rozell F, Valentí V, et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med. 2011;17:1157–67.
11. Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes. 2014;5:697–710.
12. Deleclère E, Fritz G, Verter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta. 2009;1793:993–1007.
13. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med. 2009;87:235–47.
14. Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41:421–42.
15. Ehren C, Sundérkötter C, Foell D, Vogl T, Roth J. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–66.
16. Ortega FJ, Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, Delgado E, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol. 2012;167:569–78.
17. Schmaderer C, Kemmner S, Burkhardt K, Heemann U, Baumann M. Serum myeloid-related protein 8/14 complex is associated with microalbuminuria in patients with type 2 diabetes. Ther Adv Cardiovasc Dis. 2014;8:80–8.
18. Pedersen L, Nybo M, Poulsen MK, Henriksen JE, Dahl J, Rasmussen LM. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord. 2014;14:196.
19. Markowitz J, Carson 3rd WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 1835;2013:100–9.